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AbstrACt
Introduction Inflammation, dehydration, hypotension and 
bleeding may all contribute to the development of acute 
kidney injury (AKI). Accelerated surgery after a hip fracture 
can decrease the exposure time to such contributors and 
may reduce the risk of AKI.
Methods and analysis Hip fracture Accelerated surgical 
TreaTment And Care tracK (HIP ATTACK) is a multicentre, 
international, parallel-group randomised controlled trial 
(RCT). Patients who suffer a hip fracture are randomly 
allocated to either accelerated medical assessment and 
surgical repair with a goal of surgery within 6 hours of 
diagnosis or standard care where a repair typically occurs 
24 to 48 hours after diagnosis. The primary outcome of 
this substudy is the development of AKI within 7 days of 
randomisation. We anticipate at least 1998 patients will 
participate in this substudy.
Ethics and dissemination We obtained ethics approval 
for additional serum creatinine recordings in consecutive 
patients enrolled at 70 participating centres. All patients 
provide consent before randomisation. We anticipate 
reporting substudy results by 2021.
trial registration number NCT02027896; Pre-results.
IntroduCtIon
Each year, millions of adults worldwide 
sustain a hip fracture and require surgical 
repair.1 2 Complications are common, and the 
90-day risk of mortality is 10%–20%. Short-
ening the time to surgery shows promise for 
reducing patient morbidity and mortality,3–5 
and this strategy is currently being tested in 
comparison with usual care in a multinational 
randomised controlled trial: the Hip fracture 
Accelerated surgical TreaTment And Care 
tracK (HIP ATTACK) trial.6 HIP ATTACK has 
two coprimary outcomes: the 90-day risk of 
(1) all-cause mortality and (2) major periop-
erative complications.
One lesser known complication of hip 
fracture is acute kidney injury (AKI). The 
strengths and limitations of this study
 ► Hip fracture accelerated surgical treatment and care 
track is a large international trial designed to ad-
dress whether early surgery can improve outcomes 
in patients with a hip fracture.
 ► This substudy will provide robust estimates on the 
effects of early versus later surgery on the risk of 
acute kidney injury.
 ► Patients and providers are not blinded to the inter-
vention; however, objective measures are used to 
assess outcomes and outcome assessors are blind-
ed to the intervention assignment.
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development of AKI associates with a longer hospital 
stay, increased healthcare costs and a higher risk of 
death.7–9 Approximately 15%–20% of patients who 
undergo surgery for a hip fracture will experience AKI, 
with 0.5%–1.8% receiving dialysis as a result.10–12 A hip 
fracture exposes patients to trauma, pain, bleeding, hypo-
tension and dehydration, which can lead to decreased 
renal perfusion and a heightened inflammatory state, all 
of which can contribute to the development of AKI.13 14 A 
shorter time to surgery after a hip fracture can decrease 
the exposure time to such contributors and therefore 
may reduce the risk of AKI.
This protocol describes a planned kidney substudy of 
the HIP ATTACK trial to determine if a strategy of accel-
erated medical assessment and surgical repair, compared 
with usual care, reduces the risk of AKI in patients who 
suffer a hip fracture. To do this, we worked with the inves-
tigators of the main trial during its planning stages and 
arranged to provide substudy funding to trial centres 
to collect additional follow-up measures of serum creat-
inine. A subgroup analysis by baseline chronic kidney 
disease (CKD), the most prominent risk factor for AKI, 
will also be conducted.15
MEthods And AnAlysIs
overview of the main hIP AttACK trial
The HIP ATTACK trial is a multinational, parallel-group 
superiority randomised controlled trial of patients who 
present to the emergency department with a hip frac-
ture requiring surgical repair. The main trial protocol 
is described elsewhere.6 Briefly, patients who sustained 
a hip fracture were randomly allocated (1:1) to receive 
accelerated medical assessment and surgical repair (with 
the goal of having the surgery performed within 6 hours 
after the orthopaedic diagnosis) or usual care (where 
a repair typically occurs 24–48 hours after diagnosis). 
Enrolment occurred between March 2014 and May 2019, 
and 3001 patients from 70 centres in 18 countries were 
randomised. Follow-up assessments will continue until 
August 2019 for the primary analysis. All participating 
centres obtained ethics board approval to conduct the 
trial, and all patients provided informed consent to trial 
participation before enrolling.
Patient recruitment, eligibility and informed consent
Patients were recruited from the emergency department. 
Eligibility criteria for the main HIP ATTACK trial are 
fully detailed in the published protocol.6 Eligible patients 
included those aged 45 years or older diagnosed with a 
hip fracture with a low-energy mechanism (eg, a fracture 
sustained from a fall not beyond standing height) requiring 
surgery. To align with the ability to deliver the trial interven-
tion, the diagnosis had to be made during working hours. 
Exclusion criteria were as follows: (1) patients requiring 
emergent surgery or emergent interventions for another 
reason; (2) open hip fracture; (3) bilateral hip fractures; (4) 
periprosthetic fracture; (5) therapeutic anticoagulation for 
which there is no reversing agent available; (6) patients on 
therapeutic vitamin K antagonist with a history of heparin 
induced thrombocytopaenia (7) patients refusing partici-
pation and (8) patients previously enrolled in the trial.
All patients enrolled in HIP ATTACK after the centre of 
enrolment initiated kidney data collection will be included 
in the final substudy analysis with the exception of the 
following:
i. Patients with prerandomisation end-stage kidney dis-
ease defined as prerandomisation estimated glomer-
ular filtration rate (eGFR) <15 mL/min per 1.73 m2, 
receipt of chronic dialysis or a kidney transplant. These 
patients will be excluded because the prevention of 
AKI is no longer relevant. We expect less than 2% of 
randomised patients to be excluded for this reason.
ii. Patients with no prerandomisation serum creatinine 
measurement since this measure is needed to identify 
AKI, which is defined by an acute increase in serum 
creatinine from the prerandomisation value. We ex-
pect approximately 24% of patients to be excluded 
for this reason.
randomisation
Randomisation was performed at the time of consent via 
an interactive web randomisation system maintained by 
the trial coordinating centre at the Population Health 
Research Institute, part of McMaster University in 
Hamilton, Ontario, Canada. This method ensures that the 
randomisation sequence is concealed from participating 
centres and patients. Patients were randomly allocated 
(1:1) to receive the intervention of accelerated medical 
clearance and surgery or usual care. The randomisation 
was performed using random permuted blocks of varying 
sizes that were unknown to research personnel and inves-
tigators. Stratification occurred by centre and planned 
surgery type (open reduction and internal fixation or 
arthroplasty). Due to the nature of the trial intervention, 
it was not possible to blind research personnel, health-
care providers or participants to the randomised alloca-
tion; however, data collectors and outcome adjudicators 
were unaware of the patient’s randomised allocation.
trial intervention
The trial intervention was an accelerated medical assess-
ment and surgical repair, with the goal of performing 
the surgery within 6 hours of the orthopaedic diagnosis. 
Patients underwent medical clearance by an on-call 
medical specialist (ie, an internist, geriatrician, cardiol-
ogist or anaesthesiologist) who was able to quickly come 
to the emergency department and perform the assess-
ment. Specialists used their own clinical judgement 
and weighed the potential risks and benefits of rapidly 
clearing patients for surgery.3 6 The patient’s orthopaedic 
surgeon and anaesthesiologist also had to agree that the 
patient was an appropriate surgical candidate. Following 
medical clearance, research personnel informed all rele-
vant parties (ie, the surgical booking clerk, orthopaedic 
surgeon and anaesthesiologist), and patients were moved 
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to the next available orthopaedic trauma room or elective 
operating room such that their surgeries were prioritised 
over scheduled elective cases. All other perioperative care 
was at the discretion of the attending team. Further logis-
tical details are provided in the pilot report and the main 
trial protocol.3 6
Patients randomly allocated to the usual-care group 
were placed on the wait list for surgery according to local 
standard practices.
substudy data collection
The prerandomisation (baseline) serum creatinine concen-
tration was obtained from a review of medical records in 
the 30-day period before hip fracture surgery (as part of 
routine care, most patients have their serum creatinine 
tested at the time of emergency room presentation). The 
most recent test result before randomisation will serve as 
the baseline value. To accurately capture postrandomis-
ation AKI, all study centres were given substudy funds to 
measure and record daily serum creatinine values for 7 days 
after randomisation or until hospital discharge, whichever 
came first. The highest serum creatinine value recorded 
between randomisation and hospital discharge was also 
recorded. Research personnel followed all patients daily 
during their time in hospital to improve adherence to the 
scheduled creatinine measurements. Receipt of new dial-
ysis for kidney failure was recorded at hospital discharge 
and at 30 days after randomisation.
substudy outcomes
The primary outcome of the kidney substudy is AKI, 
defined as an increase in the serum creatinine concentra-
tion from the prerandomisation value of ≥26.5 μmol/L 
(≥0.3 mg/dL) within 48 hours after randomisation or an 
increase of ≥50% within 7 days after randomisation.16
secondary definitions of AKI
Six secondary assessments of AKI will be examined to 
assess whether the primary results are robust:
1. A composite of AKI (primary outcome definition) 
or death within 48 hours after randomisation which 
will serve to account for the potential impact of early 
deaths on outcome ascertainment.
2. Stage 2 AKI (or higher), defined as a postrandomis-
ation increase in serum creatinine of 100% or more 
from the prerandomisation value within 7 days after 
randomisation or an increase to an absolute value of 
353.6 μmol/L or more (≥4.0 mg/dL) within 7 days af-
ter randomisation (when the primary outcome defini-
tion of AKI is met) or receipt of dialysis within 30 days 
after randomisation.
3. Stage 3 AKI, defined as a postrandomisation increase in 
serum creatinine of 200% or more from the prerando-
misation value within 7 days after randomisation or an 
increase to an absolute value of 353.6 μmol/L or more 
(≥4.0 mg/dL) within 7 days after randomisation or re-
ceipt of dialysis within 30 days after randomisation.
4. Receipt of dialysis within 30 days after randomisation.
5. Percentage change in serum creatinine in the first 7 
days after randomisation, defined as follows: ((peak 
postrandomisation serum creatinine—prerandomisa-
tion serum creatinine)/prerandomisation serum cre-
atinine) times 100.
6. Absolute change in serum creatinine in the first 7 days 
after randomisation, defined as follows: peak postran-
domisation serum creatinine—prerandomisation se-
rum creatinine.
statistical considerations
Sample size
The main HIP ATTACK trial enrolled 3001 patients, and 
more than 90% of these patients were enrolled after 
the initiation of the renal substudy protocol. We expect 
that approximately 74% of these patients will be eligible 
for inclusion in the kidney substudy. A sample of 1998 
patients will provide over 80% power to detect a relative 
risk (RR) reduction of 30% for the primary outcome 
of AKI (two-sided α=0.05), comparing the accelerated 
approach to usual care, assuming the incidence of AKI 
is 14% in the usual-care group, after accounting for 4% 
missing AKI status. Approximately 10%–12% of patients 
develop postoperative AKI.17 18 In hip fracture patients, 
AKI incidence is even higher, around 15%–20%.10–12 With 
these data in mind, we used a conservative 14% AKI inci-
dence for the usual care group to perform the sample 
size calculation to ensure we would have adequate statis-
tical power to detect a 30% RR reduction in the primary 
outcome, if it in truth exists.
Statistical analysis plan
In the primary analysis (intention to treat), a modified 
Poisson regression model which accounts for the treating 
centre will be used to estimate the RR and 95% CI for 
AKI comparing the intervention group to the usual-care 
group.19 20 For patients enrolled in the substudy without a 
postrandomisation serum creatinine value (expected for 
≤4% of patients), for the primary analysis model-based 
multiple imputation methods, using all available data, will 
be used to impute AKI status.18 21 22 Parameters will be esti-
mated using standard methods while allowing for extra 
imputation variability.23 A two-tailed p value <0.05 will be 
considered statistically significant. In our experience, with 
previous AKI perioperative substudies of large clinical 
trials, the unadjusted and adjusted results were virtually 
identical,18 24 25 and therefore we have not prespecified 
any adjusted analyses for this substudy.
Prespecified supporting analyses
Several supporting analyses will be conducted to examine 
whether there is concordance with the primary analysis. 
These will include a complete case analysis, an examination 
of six secondary assessments of AKI and a subgroup analysis 
of patients with prerandomisation CKD.
Complete case analysis
We will perform a complete case analysis restricted to 
patients with at least one postrandomisation serum creat-
inine measurement which is expected to involve greater 
than 96% of patients in the primary analysis.
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Alternative secondary assessments of AKI
We will examine six secondary assessments of AKI (four 
categorical and two continuous, as described above). 
RR estimates will be estimated using modified Poisson 
regression models and continuous outcomes using linear 
regression models. We will visually inspect the point 
estimates and 95% CIs and assess concordance with the 
primary analysis. Given our sample size, analyses of severe 
AKI will have limited statistical power for small effects.
Subgroup analysis
The risk of AKI will be examined in patients with and 
without CKD as defined by a prerandomisation eGFR 
<60 mL/min per 1.73 m² as assessed with the Chronic 
Kidney Disease Epidemiology Collaboration (CKD-EPI) 
equation.26 We hypothesise a greater absolute risk reduc-
tion of AKI with accelerated versus routine surgery in 
patients with CKD compared with patients without CKD. 
The p value for the interaction (CKD × intervention 
group) will be assessed in a regression model for binary 
outcome data.
Patient and public involvement statement
There was no direct patient involvement in designing this 
substudy. Previously, we reported the patient involvement 
in the main trial in the HIP ATTACK protocol paper.6
EthICs And dIssEMInAtIon
We obtained ethics approval in all centres, and all patients 
provided informed consent before randomisation (see 
online supplementary material). The dissemination 
policy will include publication in a peer-reviewed journal 
and presentations at relevant conferences. The clinical 
results of this substudy will be incorporated in the HIP 
ATTACK dissemination plan, including reporting the 
results in the HIP ATTACK open website (http://www. 
hipattacktrial. com), the HIP ATTACK Twitter account (@
HIPATTACKTrial), LinkedIn Profile, the Facebook page 
and the Reducing Global Perioperative Risk Multimedia 
Resource Center. This is an online media linked to Else-
vier’s entire international readership, through which we 
will disseminate the full-text articles, links to abstracts 
and data summaries. We expect the substudy results to be 
reported by 2021.
dIsCussIon
HIP ATTACK is a multinational randomised controlled 
trial that will determine if a strategy of accelerated medical 
clearance and surgery compared with usual care improves 
outcomes for patients with a hip fracture. The present 
protocol describes a prespecified kidney substudy of HIP 
ATTACK that will examine the effect of this strategy on the 
risk of AKI.
AKI is a known consequence of surgery. By adding addi-
tional serum creatinine measurements to HIP ATTACK, 
we will efficiently and reliably determine whether a strategy 
of accelerated medical clearance and hip surgery reduces 
the risk of AKI compared with a usual care. The strengths 
of this substudy include its randomised trial methodology 
with concealed allocation, patient recruitment from 70 
centres across 18 countries and standardised collection 
of postrandomisation serum creatinine. The primary 
outcome and statistical analysis plan are prespecified, and 
multiple sensitivity analyses are planned to examine the 
robustness of the primary results.
This substudy has some limitations. First, given the trial’s 
design, we expect that approximately 76% of patients’ 
baseline (prerandomisation) serum creatinine will be 
obtained at the time of emergency room presentation 
for hip fracture, and depending on the circumstances 
of the fracture, some of these patients’ serum creatinine 
concentrations may be unstable or elevated. Instability in 
baseline serum creatinine may make it difficult to detect 
an acute rise in postrandomisation serum creatinine, 
which is needed for the identification of AKI. To examine 
this issue, we will compare the mean baseline serum creat-
inine concentration in a subset of patients with serum 
creatinine measurements before and after hip fracture. 
Second, similar to other perioperative studies,18 24 25 urine 
output data are not collected in HIP ATTACK given the 
difficulties with accurate measurement in the setting of 
international data collection. Third, the most clinically 
relevant renal outcome would be new kidney failure 
treated with dialysis. Although we are measuring this 
outcome, we anticipate that it will occur infrequently 
(<1%), and therefore the analysis of this outcome will 
have limited statistical power. Finally, we have over 80% 
power to detect a 30% or more relative risk reduction in 
our primary outcome of AKI. As previously described, 
we will examine changes in the perioperative concentra-
tion of serum creatinine as a continuous measure, which 
might be of particular relevance if the primary outcome is 
not significant and there are concerns that this is due to a 
lack of statistical power.
In summary, this prespecified substudy of HIP ATTACK, 
a large multinational trial, will address the question 
whether a strategy of accelerated medical clearance and 
surgery for hip fracture improves renal outcomes.
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